PYXS NASDAQ
Pyxis Oncology, Inc.
1W: +0.0%
1M: -36.5%
3M: -37.0%
YTD: +60.0%
1Y: -46.8%
3Y: +12.2%
5Y: -84.0%
$1.84
+0.15 (+8.88%)
Weekly Expected Move ±12.8%
$1
$1
$2
$2
$2
Credit Risk of going bust: higher than 80% of companies Debt: 13.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.2%), Pyxis Oncology, Inc. would be worth roughly what it owes.
Total debt $17.8M against a stock market value of $116.6M.
Distance to default 2.56 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 133.2%; Altman Z'' -38.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.2%), Pyxis Oncology, Inc. would be worth roughly what it owes.
Total debt $17.8M against a stock market value of $116.6M.
Distance to default 2.56 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.8M (short-term plus half of long-term), stock volatility 133.2%; Altman Z'' -38.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-10-07
Earliest Filing
2023-08-23
Latest Filing
target: 2
acquirer: 1
licensee: 1
Counterparties (Filed by PYXS)
4 relationshipsCompanies named in PYXS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Apexigen, Inc. | — | target | Target company acquired by Pyxis Oncology in an all-stock merger transaction. | 2023-08-23 | View |
| Pyxis Oncology, Inc. | PYXS | acquirer | Acquired Apexigen, Inc. in a merger transaction. | 2023-05-24 | View |
| Apexigen, Inc. | — | target | Target company acquired by Pyxis Oncology, Inc. in a merger transaction. | 2023-05-24 | View |
| Pfizer Inc. | PFE | licensee | Pyxis Oncology entered into an amended and restated license agreement to obtain exclusive worldwide rights to Pfizer's F | 2022-10-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-01 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-09-09 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-08 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-13 | Earnings Release | View | |
| 2026-07-02 | Material Agreement; Unregistered Equity Sales; Regulation FD | Agreement | View |
| 2026-06-15 | Shareholder Vote | View | |
| 2026-05-14 | Earnings Release | View | |
| 2026-04-30 | Officer/Director Change | View | |
| 2026-03-23 | Earnings Release; Regulation FD | View | |
| 2026-02-06 | Financial Statements and Exhibits | View | |
| 2025-12-18 | Regulation FD Disclosure; Other Events | View | |
| 2025-11-03 | Results of Operations and Financial Condition | View | |
| 2025-08-14 | Results of Operations and Financial Condition | View | |
| 2025-08-04 | Other Events | View | |
| 2025-07-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-15 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2025-03-24 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-03-18 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-02-26 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR